# Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

> **NCT06205056** · PHASE1 · RECRUITING · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 78 (estimated)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]
- **BIOLOGICAL:** CH505 TF chTrimer + ALFQ [Arm 1a]
- **BIOLOGICAL:** Placebo [Arm 1a]
- **BIOLOGICAL:** Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]
- **BIOLOGICAL:** CH505 TF chTrimer +ALFQ [Arm 2a]
- **BIOLOGICAL:** Placebo [Arm 2a]
- **BIOLOGICAL:** CH505 TF chTrimer + ALFQ [Arm 1b]
- **BIOLOGICAL:** Placebo [Arm 1b]
- **BIOLOGICAL:** CH505 TF chTrimer + ALFQ [Arm 2b]
- **BIOLOGICAL:** Placebo [Arm 2b]

## Key facts

- **NCT ID:** NCT06205056
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205056, "Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06205056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*